Kenneth H Fife
Overview
Explore the profile of Kenneth H Fife including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
2656
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Baeten J, Donnell D, Mugo N, Ndase P, Thomas K, Campbell J, et al.
Lancet Infect Dis
. 2014 Oct;
14(11):1055-1064.
PMID: 25300863
Background: Antiretroviral pre-exposure prophylaxis (PrEP), with daily oral tenofovir disoproxil fumarate or tenofovir disoproxil fumarate in combination with emtricitabine, has been shown to be efficacious for HIV-1 prevention. Although the...
12.
Celum C, Morrow R, Donnell D, Hong T, Hendrix C, Thomas K, et al.
Ann Intern Med
. 2014 Jul;
161(1):11-9.
PMID: 24979446
Background: Daily oral preexposure prophylaxis (PrEP) using the antiretroviral tenofovir disoproxil fumarate (TDF) alone or in combination with emtricitabine (FTC-TDF) reduces the risk for HIV-1 acquisition. Tenofovir has in vitro...
13.
Kahle E, Kashuba A, Baeten J, Fife K, Celum C, Mujugira A, et al.
J Acquir Immune Defic Syndr
. 2014 Jan;
65(2):e90-4.
PMID: 24442233
No abstract available.
14.
Mujugira A, Magaret A, Celum C, Baeten J, Lingappa J, Morrow R, et al.
J Infect Dis
. 2013 Aug;
208(9):1366-74.
PMID: 23901094
Background: Daily suppressive therapy with valacyclovir reduces risk of sexual transmission of herpes simplex virus type 2 (HSV-2) in HSV-2-serodiscordant heterosexual couples by 48%. Whether suppressive therapy reduces HSV-2 transmission...
15.
Campbell M, Kahle E, Celum C, Lingappa J, Kapiga S, Mujugira A, et al.
J Infect Dis
. 2013 Jan;
207(7):1166-70.
PMID: 23315322
Recent data suggest that infection with human immunodeficiency virus type 1 (HIV-1) subtype C results in prolonged high-level viremia (>5 log10 copies/mL) during early infection. We examined the relationship between...
16.
Lingappa J, Thomas K, Hughes J, Baeten J, Wald A, Farquhar C, et al.
AIDS Res Hum Retroviruses
. 2012 Oct;
29(1):164-71.
PMID: 23061422
Plasma HIV-1 RNA set point is an important predictor of HIV-1 disease progression. We hypothesized that inoculum size and HIV-1 exposure prior to HIV-1 transmission may modulate set point. We...
17.
Baeten J, Donnell D, Ndase P, Mugo N, Campbell J, Wangisi J, et al.
N Engl J Med
. 2012 Jul;
367(5):399-410.
PMID: 22784037
Background: Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV-1) infection in heterosexual populations. Methods: We conducted a randomized trial of oral antiretroviral therapy...
18.
Mujugira A, Baeten J, Donnell D, Ndase P, Mugo N, Barnes L, et al.
PLoS One
. 2011 Oct;
6(10):e25828.
PMID: 21998703
Introduction: Stable heterosexual HIV-1 serodiscordant couples in Africa have high HIV-1 transmission rates and are a critical population for evaluation of new HIV-1 prevention strategies. The Partners PrEP Study is...
19.
Ndase P, Celum C, Thomas K, Donnell D, Fife K, Bukusi E, et al.
J Acquir Immune Defic Syndr
. 2011 Oct;
59(1):65-71.
PMID: 21963939
Background: As African countries scale-up couples HIV testing, little is known about sexual behaviors and HIV risk for HIV-uninfected partners in known HIV-serodiscordant relationships. Methods: We conducted a prospective study...
20.
Baker D, Ferris D, Martens M, Fife K, Tyring S, Edwards L, et al.
Infect Dis Obstet Gynecol
. 2011 Aug;
2011:806105.
PMID: 21876641
Objective: To evaluate if new imiquimod formulations using a shorter treatment duration are safe and efficacious to treat anogenital warts. Methods: In two studies 534 women ≥12 years of age...